查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1881450

抗病毒聯合療法市場－全球產業規模、佔有率、趨勢、機會和預測，按類型、藥物組合、給藥途徑、配銷通路、適應症、地區和競爭格局分類，2020-2030年預測

Antiviral Combination Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Drug Combination, By Route of Administration, By Distribution Channel, By Indications, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 187 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球抗病毒聯合療法市場規模為527.2億美元，預計2030年將以6.85%的複合年成長率成長至784.6億美元。抗病毒聯合療法是指同時使用多種抗病毒藥物治療病毒感染，旨在提高療效、降低抗藥性並更有效地抑制病毒複製。該市場的成長主要受全球範圍內愛滋病、肝炎和流感等病毒感染病例不斷增加以及抗藥性病毒株的出現所驅動，這些因素都要求採用多藥聯合療法。

市場概覽
預測期 2026-2030
2024年市場規模 527.2億美元
2030年市場規模 784.6億美元
2025-2030年複合年成長率 6.85%
成長最快的細分市場 口服
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球抗病毒聯合療法市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型（品牌藥、非品牌藥）
    • 依藥物組合分類（DNA聚合酶抑制劑、逆轉錄酶抑制劑、蛋白酶抑制劑、神經氨酸酶抑制劑、其他）
    • 依給藥途徑（口服、靜脈注射）
    • 按適應症（人類免疫缺乏病毒、肝炎、其他）
    • 按配銷通路（醫院藥房、零售藥房、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美抗病毒聯合療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲抗病毒聯合療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區抗病毒聯合療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲抗病毒聯合療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲抗病毒聯合療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球抗病毒聯合療法市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Celltrion Inc.
  • GlaxoSmithKline plc
  • Gilead Sciences, Inc
  • AbbVie, Inc.
  • Bristol-Myers Squibb Company
  • Janssen Pharmaceuticals, Inc.
  • Cipla Limited
  • Viatris Inc
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 21005

The Global Antiviral Combination Therapy Market, valued at USD 52.72 Billion in 2024, is projected to experience a CAGR of 6.85% to reach USD 78.46 Billion by 2030. Antiviral combination therapy involves the simultaneous administration of multiple antiviral drugs to treat viral infections, aiming to enhance efficacy, reduce drug resistance development, and achieve more potent viral suppression. The market's growth is primarily driven by the escalating global prevalence of viral infections such as HIV, hepatitis, and influenza, along with the increasing emergence of drug-resistant viral strains requiring multi-drug approaches.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 52.72 Billion
Market Size 2030USD 78.46 Billion
CAGR 2025-20306.85%
Fastest Growing SegmentOral
Largest MarketNorth America

Key Market Drivers

The Global Antiviral Combination Therapy Market is significantly influenced by the persistently rising prevalence of viral infections worldwide. The continuous emergence and spread of diverse viral pathogens necessitate advanced and often multi-drug treatment approaches to manage disease progression effectively and mitigate severe outcomes. For instance, according to the Pan American Health Organization / World Health Organization, in December 2023, the Region of the Americas alone reported over 4.2 million new cases of dengue fever, surpassing the previous record from 2019 by more than a million cases, as highlighted in their Situation Report N.1: Dengue Epidemiological Situation in the Americas. Such widespread outbreaks and increasing incidence rates across various viral diseases create an urgent and sustained demand for robust antiviral combination therapies that can address complex viral dynamics and patient needs.

Key Market Challenges

The high cost associated with developing novel combination therapies and their subsequent pricing presents a significant impediment to the growth of the Global Antiviral Combination Therapy Market. The substantial financial investment required for research and development directly translates into elevated drug prices, creating access barriers in numerous regions globally. This restricts patient access and limits the adoption of these advanced treatments, particularly in healthcare systems with budget constraints.

Key Market Trends

The application of Artificial Intelligence in drug discovery represents a significant trend in the global antiviral combination therapy market by accelerating the identification and optimization of novel therapeutic agents. AI algorithms are increasingly deployed to analyze complex biological data, predict drug efficacy, and streamline the screening of potential antiviral compounds, thereby reducing the time and cost associated with early-stage development. This technological integration is evidenced by the active engagement of international organizations, with the Council for International Organizations of Medical Sciences (CIOMS) holding meetings for its Working Group on Artificial Intelligence in Pharmacovigilance as recently as September 2025, signaling the industry's growing commitment to AI adoption across the pharmaceutical lifecycle.

Key Market Players

  • Celltrion Inc.
  • GlaxoSmithKline plc
  • Gilead Sciences, Inc
  • AbbVie, Inc.
  • Bristol-Myers Squibb Company
  • Janssen Pharmaceuticals, Inc.
  • Cipla Limited
  • Viatris Inc
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Antiviral Combination Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antiviral Combination Therapy Market, By Type:

  • Branded
  • Generic

Antiviral Combination Therapy Market, By Drug Combination:

  • DNA Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Neuraminidase Inhibitors
  • Others

Antiviral Combination Therapy Market, By Route of Administration:

  • Oral
  • Intravenous

Antiviral Combination Therapy Market, By Indication:

  • Human Immunodeficiency Virus
  • Hepatitis
  • Others

Antiviral Combination Therapy Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Antiviral Combination Therapy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Antiviral Combination Therapy Market.

Available Customizations:

Global Antiviral Combination Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antiviral Combination Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Branded, Generic)
    • 5.2.2. By Drug Combination (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others)
    • 5.2.3. By Route of Administration (Oral, Intravenous)
    • 5.2.4. By Indication (Human Immunodeficiency Virus, Hepatitis, Others)
    • 5.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2024)
  • 5.3. Market Map

6. North America Antiviral Combination Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Drug Combination
    • 6.2.3. By Route of Administration
    • 6.2.4. By Indication
    • 6.2.5. By Distribution Channel
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Antiviral Combination Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Drug Combination
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By Indication
        • 6.3.1.2.5. By Distribution Channel
    • 6.3.2. Canada Antiviral Combination Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Drug Combination
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Indication
        • 6.3.2.2.5. By Distribution Channel
    • 6.3.3. Mexico Antiviral Combination Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Drug Combination
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Indication
        • 6.3.3.2.5. By Distribution Channel

7. Europe Antiviral Combination Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Drug Combination
    • 7.2.3. By Route of Administration
    • 7.2.4. By Indication
    • 7.2.5. By Distribution Channel
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Antiviral Combination Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Drug Combination
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Indication
        • 7.3.1.2.5. By Distribution Channel
    • 7.3.2. France Antiviral Combination Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Drug Combination
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Indication
        • 7.3.2.2.5. By Distribution Channel
    • 7.3.3. United Kingdom Antiviral Combination Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Drug Combination
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Indication
        • 7.3.3.2.5. By Distribution Channel
    • 7.3.4. Italy Antiviral Combination Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Drug Combination
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Indication
        • 7.3.4.2.5. By Distribution Channel
    • 7.3.5. Spain Antiviral Combination Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Drug Combination
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Indication
        • 7.3.5.2.5. By Distribution Channel

8. Asia Pacific Antiviral Combination Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Drug Combination
    • 8.2.3. By Route of Administration
    • 8.2.4. By Indication
    • 8.2.5. By Distribution Channel
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Antiviral Combination Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Drug Combination
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Indication
        • 8.3.1.2.5. By Distribution Channel
    • 8.3.2. India Antiviral Combination Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Drug Combination
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Indication
        • 8.3.2.2.5. By Distribution Channel
    • 8.3.3. Japan Antiviral Combination Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Drug Combination
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Indication
        • 8.3.3.2.5. By Distribution Channel
    • 8.3.4. South Korea Antiviral Combination Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Drug Combination
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Indication
        • 8.3.4.2.5. By Distribution Channel
    • 8.3.5. Australia Antiviral Combination Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Drug Combination
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Indication
        • 8.3.5.2.5. By Distribution Channel

9. Middle East & Africa Antiviral Combination Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Drug Combination
    • 9.2.3. By Route of Administration
    • 9.2.4. By Indication
    • 9.2.5. By Distribution Channel
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Antiviral Combination Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Drug Combination
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Indication
        • 9.3.1.2.5. By Distribution Channel
    • 9.3.2. UAE Antiviral Combination Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Drug Combination
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Indication
        • 9.3.2.2.5. By Distribution Channel
    • 9.3.3. South Africa Antiviral Combination Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Drug Combination
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Indication
        • 9.3.3.2.5. By Distribution Channel

10. South America Antiviral Combination Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Drug Combination
    • 10.2.3. By Route of Administration
    • 10.2.4. By Indication
    • 10.2.5. By Distribution Channel
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Antiviral Combination Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Drug Combination
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Indication
        • 10.3.1.2.5. By Distribution Channel
    • 10.3.2. Colombia Antiviral Combination Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Drug Combination
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Indication
        • 10.3.2.2.5. By Distribution Channel
    • 10.3.3. Argentina Antiviral Combination Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Drug Combination
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Indication
        • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Antiviral Combination Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Celltrion Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. GlaxoSmithKline plc
  • 15.3. Gilead Sciences, Inc
  • 15.4. AbbVie, Inc.
  • 15.5. Bristol-Myers Squibb Company
  • 15.6. Janssen Pharmaceuticals, Inc.
  • 15.7. Cipla Limited
  • 15.8. Viatris Inc
  • 15.9. Merck & Co., Inc.
  • 15.10. F. Hoffmann-La Roche Ltd

16. Strategic Recommendations

17. About Us & Disclaimer